The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | HMA combination strategies in MDS: BLC2, CD47 & TIM-3 inhibitors
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses promising drug combinations with hypomethylating agents (HMA) in patients with myelodysplastic syndromes (MDS). Prof. Rinaldi notably highlights the addition of the BCL2 inhibitor venetoclax, as well as CD47 and TIM-3 checkpoint inhibitors, all of which are currently being evaluated in Phase II and III trials. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
